Immunocore Q2 revenue rises 18% to $115.9 million; net loss narrows to $0.8 million
Immunocore reported second-quarter 2026 results, with KIMMTRAK net product revenue of $115.9 million, up from $98.0 million a year earlier. The company posted a Q2 net loss of $0.8 million ($0.02 per share), much smaller than the $10.3 million loss in Q2 2025, and reported first-half net income of $12.2 million. The filing gives no financial guidance, and the company expects to pay approximately $120 million in sales-related rebate accruals in the second half of 2026.
Key points
- Q2 2026 KIMMTRAK net product revenue was $115.9 million, up from $98.0 million in Q2 2025; US sales were $74.9 million.
- Q2 2026 net loss was $0.8 million ($0.02 per share), compared with a $10.3 million loss ($0.20 per share) in Q2 2025.
- First-half 2026 net income was $12.2 million ($0.23 per diluted share), compared with a net loss of $5.3 million in the first half of 2025.
- Cash, cash equivalents and marketable securities were $880.2 million as of June 30, 2026; the company expects about $120 million in sales-related rebate payments in the second half of 2026.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.